Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Selecting key genes associated with ovarian cancer based on differential expression network.

Lu X, Wang J, Shan X, Li Y.

J BUON. 2017 Jan-Feb;22(1):48-57.

PMID:
28365935
2.

E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.

Sang XB, Zong ZH, Wang LL, Wu DD, Chen S, Liu BL, Zhao Y.

Oncotarget. 2017 Feb 28;8(9):14777-14793. doi: 10.18632/oncotarget.14833.

3.

HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer.

Chai Y, Liu J, Zhang Z, Liu L.

Cancer Med. 2016 Jul;5(7):1588-98. doi: 10.1002/cam4.710. Epub 2016 Apr 14.

4.

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.

5.

Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.

Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, Sawicki JA.

Cancer Res. 2016 Mar 15;76(6):1549-59. doi: 10.1158/0008-5472.CAN-15-2073. Epub 2016 Feb 26. Erratum in: Cancer Res. 2016 Jun 1;76(11):3437.

6.

miR-31 Reduces Cell Growth of Papillary Thyroid Carcinoma by RNA-Binding Protein HuR.

Wu D, Wang B, Shang J, Song J, Zhang H.

Clin Lab. 2015;61(11):1625-34.

7.

HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R.

Hum Pathol. 2016 Feb;48:95-101. doi: 10.1016/j.humpath.2015.09.027. Epub 2015 Oct 22.

PMID:
26640230
8.

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C.

Oncotarget. 2015 Aug 7;6(22):18966-79.

9.

MiR-200c and HuR in ovarian cancer.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

BMC Cancer. 2013 Feb 8;13:72. doi: 10.1186/1471-2407-13-72.

10.

HuR regulates beta-tubulin isotype expression in ovarian cancer.

Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

Cancer Res. 2010 Jul 15;70(14):5891-900. doi: 10.1158/0008-5472.CAN-09-4656. Epub 2010 Jun 29.

11.

HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.

Yi X, Zhou Y, Zheng W, Chambers SK.

Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):93-8. doi: 10.1111/j.1479-828X.2008.00937.x.

PMID:
19281587
12.

Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells.

Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, Dent P, Kordula T, Zhou H, Fang X.

FASEB J. 2008 Aug;22(8):2639-51. doi: 10.1096/fj.07-101428. Epub 2008 Mar 24.

13.

Prognostic role of HuR in hereditary breast cancer.

Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A.

Clin Cancer Res. 2007 Dec 1;13(23):6959-63.

14.

Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.

Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC Jr.

Clin Cancer Res. 2006 Apr 15;12(8):2404-13.

15.

Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.

Erkinheimo TL, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, Butzow R, Ristimäki A.

Gynecol Oncol. 2005 Oct;99(1):14-9.

PMID:
16126263
16.

Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R, Ristimäki A.

Cancer Res. 2003 Nov 15;63(22):7591-4.

Supplemental Content

Loading ...
Support Center